Biogen Inc. (ETR:IDP)
116.90
+1.65 (1.43%)
Aug 15, 2025, 5:35 PM CET
Biogen Revenue
Biogen had revenue of $2.65B USD in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $10.00B, up 3.36% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.00B
Revenue Growth
+3.36%
P/S Ratio
2.04
Revenue / Employee
$1.31M
Employees
7,605
Market Cap
17.35B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
Biogen News
- 2 days ago - BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 3 days ago - How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment - Benzinga
- 5 days ago - Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - GlobeNewsWire
- 5 days ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire
- 14 days ago - Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio - Seeking Alpha
- 16 days ago - Biogen raises 2025 EPS guidance to $15.50-$16 as new launches drive 7% revenue growth - Seeking Alpha
- 16 days ago - Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Biogen Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha